Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

And Denali (Nasdaq: DNLI) is taking a "small" equity stake as well, Tenvie leaders said. What's more, 35-employee Tenvie is subleasing 15,000 square feet from Denali in South San Francisco.

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) gapped down prior to trading on Tuesday after JPMorgan Chase & Co. lowered their price target on the stock from $28.00 to $24.00.

NEW YORK, NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account ...

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

Stifel’s continued support for Denali Therapeutics stock follows a recent decline in share value after the failure of another drug candidate, eIF2B, which the analysts considered high-risk and not ...